IAVI AMR team based in La Jolla achieved multifunctional antibody responses.
Public source
Publisher name
Public post
Great work from our AMR team based in La Jolla!
Company
IAVI
Translating science into global health impact.
- Industry
- Research Services
- Location
- New York, US
- Company size
- 201–500 employees
About IAVI
Translating scientific discoveries into affordable, globally accessible public health solutions. IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases.
See moreLatest activity
Latest activity from IAVI
4 signals
Research & Knowledge
IAVI published its 2025 Annual Report highlighting progress toward broadly neutralizing antibodies for HIV, the IMAGINE trial for MTBVAC, and the Sudan virus vaccine response.
Presence & Recognition
IAVI is co-organizing the 8th Global Forum TBVax with Stop TB Partnership Working Group on New TB Vaccines, TuBerculosis Vaccine Initiative (TBVI), and the Universidad de Zaragoza.
Research & Knowledge
IAVI scientists analyzed immune responses induced by Shigella infection in nonhuman primates following a partnership with researchers at Wisconsin National Primate Research Center following a years-long Shigella outbreak.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
La Jolla Institute for Immunology
La Jolla Institute for Immunology postdoctoral researcher Erik Ehinger won top honors in the Nucleate San Diego Activator Program.
People
MRIGlobal
MRIGlobal features Kristine Werking, Karen Peltier, and Michaela Hoffmeyer as colleagues advancing the development of research-use-only assays and 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 diagnostics.
Research & Knowledge
CEPI (Coalition for Epidemic Preparedness Innovations)
CEPI (Coalition for Epidemic Preparedness Innovations) published its latest newsletter highlighting ongoing efforts to close the MPox vaccine access gap, the latest progress in the fight against Bundibugyo ebolavirus, funding for a fifth vaccine candidate, the initiation of another Phase 1 trial, and R&D news.
Research & Knowledge
IrsiCaixa
IrsiCaixa researchers published a new study showing that a new model improves the development of human immune cells involved in HIV persistence, detecting more HIV-associated signals in tissues than conventional models.
People
International Vaccine Institute (IVI)